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Abstract
Streptococcus agalactiae group B (S. agalactiae gr. B) is widespread in nature mainly causes bacterial 
septicemia and neonatal meningitis. The current study was attempted to investigate the effect of biofield treatment 
on S. agalactiae gr. B with respect of antimicrobial sensitivity, biochemical reactions and bio typing. S. agalactiae 
gr. B strain was used in this experiment bearing the American Type Culture Collection (ATCC 12386) number 
and stored according to the recommended storage protocol. The revived and lyophilized state of ATCC strains 
of S. agalactiae gr. B were selected for the study. Gr. I was considered as control. Both revived (Group; Gr. II) 
and lyophilized (Gr. III) strains of S. agalactiae gr. B were subjected to Mr. Trivedi’s biofield treatment. Gr. II was 
assessed on day 5 and day 10 while Gr. III on day 10 with respect to the control (Gr. I) using MicroScan Walk-Away® 
system. Although biofield treatment did not show any change with respect to susceptibility pattern. However the 
minimum inhibitory concentration of S. agalactiae gr. B showed significant (70.37%) alteration, out of twenty-seven 
tested antimicrobials, among which in Gr. II i.e. 62.96% on day 5 and 66.67% on day 10 while no alteration was found 
in lyophilized group (Gr. III) as compared to the control. Moreover, the improvement of MIC value of norfloxacin was 
observed by two-fold (8 to ≤4 µg/mL) in Gr. II on day 10 after biofield energy treatment as compared to the control. 
It was observed that overall 48.28% biochemical reactions, out of twenty-nine were altered in Gr. II with respect to 
the control. Moreover, biotype numbers were changed in Gr. II on day 5 (777777615) and on day 10 (757677405) 
as compared to the control (237147047). The results suggest that biofield treatment has significant impact on S. 
agalactiae gr. B in revived treated cells (Gr. II) with respect to MIC values, biochemical reactions pattern and biotype 
number. 
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Introduction
Group B Streptococci (GBS), or Streptococcus agalactiae group B, 
are Gram-positive, non-spore forming, non-motile, β-hemolytic and 
chain-forming cocci bacteria. It is mainly inhabitant in human gut flora 
and female urogenital tract [1]. Pregnant women [2] and neonates [3] are 
the main victim host of this organism. It can be transferred to neonates 
through the birth canal and causes bacterial septicaemia and neonatal 
meningitis [4]. Most of GBS, produce Christie-Atkins-Munch-Petersen 
(CAMP) factor or protein B an extracellular cytolytic protein and 
β-lysin from Staphyllococcus species are jointly lysed the erythrocytes 
[5]. It is estimated that in US over 70,000 cases of GBS diseases 
were prevented [6]. Several antibiotics such as penicillin, ampicillin, 
amoxicillin, cephalosporins (all three generations), macrolides, 
clindamycin and vancomycin (as alternative) have been used to treat 
against GBS infections. Among above mentioned antibiotics penicillin 
is the drug of choice next to cefazolin. However, it also have certain 
limitations such as high minimum inhibitory concentration (MIC), a 
factor associated with high level of bacteremia and more concentration 
of microbes in tissue, especially in cerebrospinal fluid [7,8]. Therefore, 
some alternative treatment strategies are needed to overcome these 
lacunas against β-hemolytic strain of gr. B Streptococci. Biofield 
treatment has been known as an alternative approach that may be 
useful for S. agalactiae group B infected patients.
Researchers have shown that short-lived electrical events or action 
potential exist in the several type of mammalian cells such as neurons, 
muscles, and endocrine cells [9]. For instance, when the cells present 
in central nervous system of human body communicate with each 
another by means of electrical signals that propagate along the nerve 
impulses. Therefore, it was hypothesized that biofield exists around 
the human body and evidence was found using electromyography, 
electrocardiography and electroencephalogram [10]. Thus, the human 
body emits the electromagnetic waves in the form of bio-photons, 
which surrounds the body and it is commonly known as biofield. 
Therefore, the biofield consists of electromagnetic field, being generated 
by moving electrically charged particles (ions, cell, molecule etc.) inside 
the human body. Rivera-Ruiz reported that electrocardiography has 
been extensively used to measure the biofield of human body [11]. 
Thus, human has the ability to harness the energy from environment or 
Universe and can transmit into any living or nonliving object(s) around 
the Globe. The objects always receive the energy and responding into 
useful way that is called biofield energy and the process is known as 
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biofield treatment that is also called as Trivedi effect®. Mr. Trivedi’s 
unique biofield treatment has been known to transform the structural, 
physical, and thermal properties of several metals in material science 
[12-14], improved the overall productivity of crops [15,16], altered 
characteristics features of microbes [17-19] and improved growth and 
anatomical characteristics of various medicinal plants [20,21].
Due to the clinical significance of this organism and literature 
reports on biofield treatment, the present work was undertaken to 
evaluate the impact of biofield treatment on S. agalactiae group B 
in relation to antimicrobials susceptibility and bio typing based on 
various biochemical characters.
Materials and Methods
S. agalactiae group B, American Type Culture Collection (ATCC 
12386) strains were procured from MicroBioLogics, Inc., USA, in 
two sets A and B. Two different sealed packs were stored with proper 
storage conditions until further use. All the tested antimicrobials and 
biochemicals were procured from Sigma-Aldrich, MA, USA. The 
antimicrobial susceptibility, biochemical reactions and biotype number 
were estimated with the help of MicroScan Walk-Away® (Dade Behring 
Inc., West Sacramento, CA, USA) using Positive Breakpoint Combo 20 
(PBPC 20) panel with respect to the control group.
Experimental design
Two ATCC samples A and B of S. agalactiae gr. B were grouped 
(Gr.). ATCC A sample was revived and divided into two parts Gr.I 
(control) and Gr.II (revived); likewise, ATCC B was labeled as Gr.III 
(lyophilized). 
Biofield treatment strategy
The Gr. I remained as untreated. The treatment Gr. II and III 
in sealed pack were handed over to Mr. Trivedi for biofield energy 
treatment under laboratory condition. Mr. Trivedi provided the 
treatment through his energy transmission process which includes 
bioenergy emission to the treated groups (Gr. II and Gr. III) without 
touching the samples. After treatment, sample was handed over in the 
same condition and stored at standard conditions as per the standard 
experimental protocol. An optimum precautionary measure were taken 
while evaluating the study parameters throughout the experiments. 
The differences in parameters before and after the treatment were 
noted and compared. Gr.II was assessed at two time point i.e. on day 
5 and day 10, while Gr. III was assessed on day 10 for antimicrobial 
susceptibility, MIC, biochemical reactions pattern, and biotyping.
Antimicrobial susceptibility test
Investigation of antimicrobial susceptibility of S. agalactiae gr. B 
was carried out with the help of automated instrument, MicroScan 
Walk-Away® system using PBPC 20 panel as per the clinical and 
laboratory standards institute (CLSI) guidelines. The test was carried 
out on MicroScan, which was miniaturized of the broth dilution 
susceptibility test that has been dehydrated. Briefly, the standardized 
suspension of S. agalactiae gr. B was inoculated, rehydrated, and then 
subjected to incubation for 16 hours at 35°C. The detailed experimental 
procedures and conditions were followed as per the manufacturer's 
instructions. The antimicrobial susceptibility pattern and MIC were 
determined by observing the lowest antimicrobial concentration 
showing growth inhibition [22]. 
Biochemical reaction studies
Biochemical reactions of S. agalactiae gr. B were determined using 
MicroScan Walk-Away®, system with PBPC 20 panel [22]. Biochemicals 
used in the study were arabinose, arginine, bacillosamine, bile 
esculin, β-lactamases, crystal violet, hemolysin, indoxyl phosphatase, 
inulin, acidification lactose, mannitol, mannose, micrococcus screen, 
sodium chloride, nitrate, novobiocin, optochin, p-nitro phenyl β-D-
glucuronide, p-nitro phenyl β-D-galactopyranoside, phosphatase, 
pyruvate, pyrolidonyl arylamidase, raffinose, rambose, sorbitol, 
thymidine free growth, acidification trehalose, urea, and Voges-
Proskauer. 
Identification of organism by biotype number 
The biotype number of S. agalactiae gr. B was determined on 
MicroScan Walk-Away® processed panel data report with the help of 
biochemical reactions data [22].
Results and Discussion
Antimicrobial susceptibility test
The outcomes of MIC values of tested antimicrobials against S. 
agalactiae gr. B after biofield treatment are summarized in Table 1. The 
data were analyzed using automated system and compared with respect 
to the control. In this experiment, twelve antibiotics were used to 
investigate the susceptibility pattern on GBS viz. ampicillin, cefepime, 
cefotaxime, ceftriaxone, chloramphenicol, clindamycin, levofloxacin, 
linezolid, ofloxacin, penicillin, tetracycline, and vancomycin. Out 
of these, five antibiotics showed susceptible in the control sample. It 
has been evidenced from literatures that penicillin and its derivatives 
are the choice of drugs against gr. B streptococcal infection [8,9]. 
However, biofield treatment did not show any alteration with respect 
to susceptibility pattern in all the treated groups after biofield treatment 
(data not shown). Besides sensitivity assay, the MIC values of tested 
antimicrobials were significantly (70.37%) altered out of twenty seven 
as compared to the control. The MIC value of norfloxacin was reduced 
by two-fold to ≤ 4 µg/mL after biofield treatment in Gr. II on day 10 
as compared to the control (8 µg/mL). The MIC values of cefazolin, 
cephalothin, and chloramphenicol were changed from ≤ 8 to >16 µg/
mL in Gr. II on day 5 and 10 as compared to the control. The MIC values 
of rifampin and synercid were changed from ≤ 1 to >2 µg/mL in Gr. II 
on day 5 and 10 as compared to the control. Alteration of MIC values of 
cefotaxime and ceftriaxone were changed from ≤8 to 32 µg/mL in Gr. 
II on day 5 and 10 as compared to the control. Moreover, MIC values 
of amoxicillin/k-clavulanate and trimethoprim/sulfamethoxazole 
were slightly changed from ≤4/2 to >4/2 µg/mL (on day 5 and 10) and 
≤2/38 to >2/38 µg/mL (on day 5) respectively in Gr. II after biofield 
treatment as compared to the control. Antimicrobial linezolid showed 
an alteration of MIC value in Gr. II on day 5 (>4 µg/mL) and on day 
10 (4 µg/mL) as compared to the control. Besides this, alteration of 
MIC values were observed in case of penicillin (≤ 0.03 to >8 µg/mL), 
vancomycin (≤ 0.2 to >16 µg/mL), nitrofurantoin (≤ 32 to >64 µg/mL), 
clindamycin (≤ 0.5 to >2 µg/mL), ampicillin (≤ 0.25 to >8 µg/mL) and 
ampicillin/sulbactam (≤ 8/4 to >16/8 µg/mL) in Gr. II on day 5 and 10 
as compared to the control. The MIC value of tetracycline was changed 
from ≤ 4 to 8 µg/mL in Gr. II on day 10 and MIC value of oxacillin 
was changed from ≤ 0.25 to >2 µg/mL (on day 5) and 2 µg/mL on day 
10 in Gr. II as compared to control. Antimicrobials did not show any 
change in MIC value in Gr. III as compared to the control after biofield 
treatment. Seventeen out of twenty seven (62.96%) antimicrobials 
showed alteration of MIC value in Gr. II on day 5 and 66.67% (eighteen 
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such as raffinose (RAF) and sorbitol (SOR) showed an alteration of 
biochemical reaction i.e. negative (-) to positive (+) in Gr. II on day 5 
while remained negative in Gr. II on day 10 and in Gr. III as compared 
to the control. 
The one of the key characteristic feature for GBS is complete 
lysis of red blood cells and metabolization of sugars by fermentation 
process. Hence, in control sample the positive reaction of hemolysin 
(HEM) indicated β-hemolysis of erythrocytes and positive reaction of 
acidifying lactose (LAC) indicated the production of lactic acid as bi-
product. The data was supported with literature [23]. Similarly, based 
on existing literature pyrolidonyl arylamidase (PYR) has negative 
reaction in group B streptococcal species while positive reaction in 
group A streptococcal. Control data of PYR was well supported with 
literature data [24]. However, after biofield treatment the negative 
reaction was altered in Gr. II, assessed on day 5 as well as day 10 due to 
change of enzymatic reaction.
Overall, 48.28% biochemical reactions were altered in tested 
twenty-nine biochemicals with respect to the control after biofield 
treatment. In both time points of Gr. II (day 5 and 10) 41.38% (twelve 
out of twenty-nine) biochemical reactions were altered as compared 
to the control. About 51.72% out of twenty-nine biochemicals, such as 
arabinose (ARA), bacillosamine (BAC), β-lactamase (BL), hemolysin 
(HEM), indoxyl phosphatase (IDX), inulin (INU), acidification lactose 
(LAC), mannose (MNS), micrococcus screen (MS), optochin (OPT), 
glycosidase (PGT), phosphatase (PHO), thymidine free growth (TFG), 
acidification trehalose (TRE), and Voges-Proskauer (VP) did not 
out of twenty seven) on day 10 as compared to the control after biofield 
treatment. Eight, out of twenty seven tested antimicrobials (29.63%) 
viz. cefepime, ciprofloxacin, gatifloxacin, imipenem, levofloxacin, 
moxifloxacin, ofloxacin and piperacillin/tazobactam did not show any 
alteration of MIC values in all the treated cells of GBS as compared to 
the control (Table 1). 
Biochemical reactions studies
Study of biochemical reactions can be utilized to identify 
the enzymatic and metabolic characteristic features of microbes. 
Microorganisms can be categorically differentiated based on their 
utilization of specific biochemicals as nutrients during the process of 
metabolism or enzymatic reactions. The specific biochemical showed 
some changes against S. agalactiae gr. B after biofield treatment that 
are shown in Table 2. Biochemicals such as bile esculin (BE), crystal 
violet (CV), mannitol (MAN), sodium chloride (NaCl), nitrate (NIT), 
novobiocin (NOV), pyrolidonyl arylamidase (PYR) and urea (URE) 
were changed from negative (-) to positive (+) reactions in revived 
treated group (Gr. II) on day 5 and 10, but remained same i.e. negative 
(-) reaction in lyophilized treated cells (Gr. III) with respective to 
control. Arginine (ARG) and glycosidase (PGR) were converted 
from positive (+) to negative (-) reactions in Gr. II on day 10, while 
remained unchanged i.e. positive (+) on day 5 in Gr. II and in Gr. III as 
compared to the control in biofield treated S. agalactiae gr. B. Similarly, 
pyruvate (PRV), and rambose (RBS) were converted from positive (+) 
to negative (-) reactions on both days in Gr. II, while did not show any 
change in Gr. III as compared with the control. Moreover, biochemicals 
Table 1: Effect of biofield treatment on Streptococcus agalactiae group B to minimum inhibitory concentration (MIC) of tested antimicrobials.
S. No. Antimicrobial Type of Response
Gr. I Gr. II Gr. III
Day 5 Day 10
1. Amoxicillin/k-clavulanate ≤4/2 >4/2 >4/2 ≤4/2
2. Ampicillin/sulbactam ≤8/4 >16/8 >16/8 ≤8/4
3. Ampicillin ≤0.25 >8 >8 ≤0.25
4. Cefazolin ≤8 >16 >16 ≤8
5. Cefepime ≤8 ≤8 ≤8 ≤8
6. Cefotaxime ≤8 32 32 ≤8
7. Ceftriaxone ≤8 32 32 ≤8
8. Cephalothin ≤8 >16 >16 ≤8
9. Chloramphenicol ≤8 >16 >16 ≤8
10. Ciprofloxacin ≤1 ≤1 ≤1 ≤1
11. Clindamycin ≤0.5 >2 >2 ≤0.5
12. Gatifloxacin ≤2 ≤2 ≤2 ≤2
13. Imipenem ≤4 ≤4 ≤4 ≤4
14. Levofloxacin ≤2 ≤2 ≤2 ≤2
15. Linezolid ≤2 >4 4 ≤2
16. Moxifloxacin ≤2 ≤2 ≤2 ≤2
17. Nitrofurantoin ≤32 >64 >64 ≤32
18. Norfloxacin 8 8 ≤4 8
19. Ofloxacin ≤2 ≤2 ≤2 ≤2
20. Oxacillin ≤0.25 >2 2 ≤0.25
21. Penicillin ≤0.03 >8 >8 ≤0.03
22. Piperacillin/tazobactam ≤4 ≤4 ≤4 ≤4
23. Rifampin ≤1 >2 >2 ≤1
24. Synercid ≤1 >2 >2 ≤1
25. Tetracycline ≤4 ≤4 8 ≤4
26. Trimethoprim/sulfamethoxazole ≤2/38 >2/38 ≤2/38 ≤2/38
27. Vancomycin ≤2 >16 >16 ≤2
MIC values are presented in µg/mL; Gr.: Group
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show any change in all the treated groups after biofield treatment as 
compared to the control.
Identification of organism by biotype number 
The species (S. agalactiae gr. B) was identified based on variety of 
conventional biochemical characters and biotyping. Biotype number of 
particular organism was evaluated after interpreting the results of the 
biochemical reactions. The biotype number then led to the particular 
organism identification. In this experiment, biotyping was performed 
using automated systems. Results showed changes of biotype numbers 
in the biofield treated Gr. II (on day 5 and 10) and Gr. III (on day 
10) without alteration of organism. Based on the biochemical data, 
biotype number was changed in treated Gr. II on day 5 (777777615, 
S. agalactiae group B) and on day 10 (757677405, S. agalactiae group 
B) with respect to the control (237147047) i.e. S. agalactiae group B 
(Table 3). Biotyping, covers the overall cellular pattern of enzymatic 
activities of any organism. GBS can be characterized based on analysis 
of biochemical properties with CAMP, Na-hippurate positive and 
esculin negative as key characters [25]. In this experiment, bile esculin 
also showed negative (-) reaction in control sample, that directly 
correlated with literature. This negative reaction of esculin was altered 
after biofield treatment in revived treated cells of GBS. It was indicated 
that biofield treatment has the ability to alter the biochemical pattern 
which may be due to change the enzymatic reaction. So, it is assumed 
that these changes of biotype number without alteration in organism 
may be due to change of metabolic and/or enzymatic reactions of GBS. 
Biofield treatment may responsible for alteration in microorganism 
at genetic and/or enzymatic level, which probably act on receptor protein. 
While altering receptor protein, ligand-receptor/protein interactions 
may alter that could lead to different phenotypic characteristics [26]. 
Biofield treatment might induce a significant changes in revived 
strain of GBS and altered the MIC values, biochemical reactions, and 
ultimately change the biotype number of microorganism. 
Conclusion
Altogether, the biofield treatment has significantly altered 70.37%, 
(out of twenty-seven) the MIC values of tested antimicrobials against 
the strain of S. agalactiae gr. B. Norfloxacin was improved the MIC value 
by two-fold (8 to ≤4 µg/mL) in Gr. II on day 10 after biofield energy 
treatment as compared to the control. Additionally, it also significantly 
(48.28%) altered the biochemical reactions pattern of biofield energy 
treated strain of S. agalactiae gr. B. On the basis of utilization of group 
B streptococcal specific biochemicals, change in metabolic reactions led 
to variation of biotype number in all the treated groups without change 
of organism after biofield treatment with respect to the control. Based 
on above findings, it is assumed that Mr. Trivedi’s biofield treatment is 
Table 2: Effect of biofield treatment on Streptococcus agalactiae group B to the biochemical reaction pattern.
S. No. Code Biochemical Gr. I Type of Response
Gr. II Gr. III
Day 5 Day 10
1. ARA Arabinose - - - -
2. ARG Arginine + + - +
3. BAC Bacillosamine + + + +
4. BE Bile esculin - + + -
5. BL Beta lactamases NR NR NR NR
6. CV Crystal violet - + + -
7. HEM Hemolysin + + + +
8. IDX Indoxyl phosphatase + + + +
9. INU Inulin - - - -
10. LAC Acidification lactose + + + +
11. MAN Mannitol - + + -
12. MNS Mannose + + + +
13. MS Micrococcus screen + + + +
14. NaCl Sodium chloride - + + -
15. NIT Nitrate - + + -
16. NOV Novobiocin - + + -
17. OPT Optochin + + + +
18. PGR Glycosidase* + + - +
19. PGT Glycosidases# + + + +
20. PHO Phosphatase + + + +
21. PRV Pyruvate + - - +
22. PYR Pyrolidonyl arylamidase - + + -
23. RAF Raffinose - + - -
24. RBS Rambose + - - +
25. SOR Sorbitol - + - -
26. TFG Thymidine free growth + + + +
27. TRE Acidification trehalose + + + +
28. URE Urea - + + -
29. VP Voges-Proskauer + + + +
‘-’ (negative); ‘+’ (positive); Gr.: Group; NR: Not reported; *PGR: p-nitro phenyl β-D- glucuronide; #PGT: p-nitro phenyl β-D-galactopyranoside.
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an alternative approach to alter the antibiogram profile of S. agalactiae 
gr. B.
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